GBT Guerbet SA

Guerbet : Change in General Management

Guerbet : Change in General Management

Change in General Management

Villepinte France, September 22nd, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Jérôme Estampes as interim Chief Executive Officer.

Jérôme Estampes replaces Mr. David Hale, who is leaving the Group to pursue new projects. The Board of Directors thanks him for his work since joining Guerbet in February 2018, initially as Chief Commercial Officer and then as Chief Executive Officer since January 1, 2020.

Jérôme Estampes has been with the Group since 2019 as Chief Administrative and Financial Officer, overseeing IT, business development, and licensing. In this role, he has gained an excellent understanding of the Group’s current financial, operational, and commercial challenges.

Supported by the Board of Directors, Jérôme Estampes can rely on the support and experience of Guerbet’s Executive Committee to ensure a smooth transition, continue implementing transformation measures, and deploy the Group’s commercial strategy.

The Nominations and Remuneration Committee has already begun the recruitment process for the future Chief Executive Officer.

Next Event:

Publication of 2025 First Half Results

September 24, 2025, after market close

About Guerbet

Guerbet is a global leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging. Guerbet invests 10% of its annual revenue in research and development, with dedicated innovation centers in France and the United States. The company (GBT) is publicly traded on Euronext Paris and reported €786 million in revenue in 2023.

For more information, visit:

Attachment



EN
22/09/2025

Underlying

GBTGuerbet SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guerbet SA

 PRESS RELEASE
Free
GBT GUERBET SA

GUERBET : 2025 full-year results.

GUERBET : 2025 full-year results. 2025 full-year results Revenue: €786.4 million, down 3.5% at CER1 and like-for-like2, mainly due to the fall in activity in FranceProfitability: restated EBITDA margin3 of 12.0% (at the high end of the adjusted range communicated in December)Net Income: loss of €112.7 million, which includes a non-recurring impairment of €86 millionFree cash flow: in positive territory at €19.2 millionIndebtedness: net debt/EBITDA ratio of 4.0x, below the ceiling of 4.8x set in December 2025 under the waiver obtained by the Group from its lenders. 2026 Significant negat...

8h / 28m 1 EN
 PRESS RELEASE
Free
GBT GUERBET SA

GUERBET : Résultats annuels 2025.

GUERBET : Résultats annuels 2025. Résultats annuels 2025 Chiffre d’affaires : 786,4 M€, soit un repli de 3,5% à TCC1 et périmètre comparable2, dû essentiellement à la baisse de l’activité en FranceRentabilité : la marge d’EBITDA retraité3   ressort à 12,0% (dans le haut de la fourchette ajustée communiquée en décembre)Résultat net : il s’établit à -112,7 M€ incluant une dépréciation exceptionnelle de 86 M€ constatée à l’issue des tests de dépréciationFree Cash-Flow : en territoire positif à hauteur de 19,2 M€Endettement : ratio d’endettement financier net /EBITDA de 4,0x inférieur au plaf...

8h / 28m 1 EN
 PRESS RELEASE
Free
GBT GUERBET SA

GUERBET : Change in Guerbet’s Board of Directors.

GUERBET : Change in Guerbet’s Board of Directors. Change in Guerbet’s Board of Directors Villepinte, March 11th, 2026: Guerbet (FR0000032526 GBT), a global leader in contrast agents and solutions for medical imaging, today announced, at its Board of Directors’ meeting, the appointment of Mr. Antoine Fady as “censeur” (non-voting director) effective immediately. The appointment of Mr. Antoine Fady as a Director will be submitted for approval at the next Shareholders’ Meeting. Following this Shareholders’ Meeting, it will be proposed that the Board of Directors of Guerbet appoint Mr. Antoi...

8h / 28m 1 EN
 PRESS RELEASE
Free
GBT GUERBET SA

GUERBET : Evolution du Conseil d’Administration de Guerbet.

GUERBET : Evolution du Conseil d’Administration de Guerbet. Evolution du Conseil d’Administration de Guerbet Villepinte, le 11 mars 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination ce jour lors du Conseil d’Administration, de Monsieur Antoine FADY en qualité de censeur avec effet immédiat. La nomination de Monsieur Antoine Fady en qualité d’administrateur sera soumise pour approbation à la prochaine Assemblée Générale. À la suite de cette Assemblée Générale, il sera proposé au Conseil d’Administr...

8h / 28m 1 EN
 PRESS RELEASE
Free
GBT GUERBET SA

GUERBET : Nombre d'actions et de droits de vote composant le capital d...

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2026 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l’AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d’actions composant le capital de la société s’ils ont varié par ra...

February 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch